Investor Presentation Q1 2023
Commercial
execution
Purpose and
sustainability
(ESG)
4
Investor presentation
First three months of 2023
Strategic Aspirations 2025 | Highlights first three months 2023
Progress towards zero environmental impact
Carbon emissions decreased by 21% vs Q1 20191
Adding value to society
Medical treatment provided to 37.2 million people living
with diabetes
Reaching more than 42,000 children in Changing
Diabetes in Children programme
Being recognised as a sustainable employer
Share of women in senior leadership positions has
increased to 39% from 37% end of March 2022
ピ
Diabetes value market share increased by 1.7%-points
to 32.2%2
Obesity care sales of DKK 7.8 billion (+124% at CER)
Rare disease sales of DKK 4.6 billion (-16% at CER)
IIIIIO
Innovation and
therapeutic focus
•
•
Further raise innovation bar for Diabetes treatment
Regulatory submission of once-weekly insulin icodec
Completion of phase 3 trial PIONEER PLUS
Completion of phase 1/2 trials with GLP-1/GIP
Develop superior treatment solutions for obesity
Phase 3a trials REDEFINE 2 & 3 initiated with CagriSema
Strengthen and progress Rare Disease pipeline
.
•
•
.
Somapacitan approved in the US for GHD in children
CRL received for concizumab in the US
Establish presence in Other serious chronic diseases
Phase 1 trials initiated with cell therapy treatment
1Scope 1,2 and partial scope 3 limited to CO2 emissions from business flights and product distribution; 2MAT (Moving annual total) value market share
VP: Vice president; CER: Constant exchange rates; CRL: Complete Response Letter; US: United States; GHD: Growth Hormone Deficiency; GIP: Gastric inhibitory polypeptide; GLP-1: Glucagon Like Peptide 1
Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth
Financials
Sales growth of 25% (CER) and operating profit growth of
28% (CER)
Operational leverage reflecting sales growth
Free cash flow of DKK 24.8 billion and DKK 23.5 billion
returned to shareholders
Novo NordiskⓇView entire presentation